Discuss Tri-Heal on glp1chat
Join the forum to discuss research with other members.
At a glance
Tri-Heal is a blend of TB-500, BPC-157 and KPV, rather than one molecule. The first two appear in tissue-repair research, while KPV is studied for inflammatory signals. Putting them together creates a new preparation whose effects cannot be calculated by adding the separate studies.
TB-500-related work examines how cells move into injured tissue; BPC-157 studies look at support fibers and blood vessels; KPV experiments measure inflammatory messages. These are different steps in a repair response, which explains the blend's name and research rationale. The proportions and exact TB-500 sequence still matter. A claim that this complete blend speeds healing needs a study of the mixture itself, not just studies of its parts.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][4][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tri-Heal.
Source-reported adverse effects and cautions
Note: Human clinical data on this specific combination is limited; observations are extrapolated from studies of individual components.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 45 mg · 3 source tables
Standard 8-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
*Precision Note: For doses ≤10 units (≤0.10 mL), consider using 30-unit or 50-unit insulin syringes for improved readability and accuracy. Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to optimize syringe accuracy across all dose levels.
Extended 12-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
Extended 16-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
| Weeks 13–14 | 3500 mcg | 3.5 mg | 23.3 units | 0.233 mL |
| Weeks 15–16 | 4000 mcg | 4.0 mg | 26.7 units | 0.267 mL |
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support tissue repair, regeneration, and inflammation modulation through synergistic peptide action[1][2][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500–4000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 45 mg vial (15 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Suggested daily titration approach.
- Start: 500 mcg daily; increase by 500 mcg every 2 weeks as tolerated.
- Target: 1500–2000 mcg daily by Weeks 5–8 (standard); up to 3000–4000 mcg for extended protocols.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites systematically.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the lyophilized cake.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with date and concentration (15 mg/mL); refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) or colder (ideally −80 °C / −112 °F for long-term) in dry, dark conditions[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks; prepare aliquots if needed and avoid freeze–thaw cycles[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry completely before proceeding.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[8].
- Dispose of used syringes in an approved sharps container; never recap or reuse needles.
Materials & quantity planning
Source materials checklist · 45 mg
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (Tri-Heal, 45 mg each):
- 8 weeks (56 doses, ~70 mg total): 2 vials
- 12 weeks (84 doses, ~147 mg total): 4 vials
- 16 weeks (112 doses, ~252 mg total): 6 vials
- Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Recommendation: Include 30-unit or 50-unit syringes for the early low-dose phases (Weeks 1–4) where precision is critical.
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 45 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Public health resource
HSS Journal / PMC (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Frontiers in Endocrinology (2021) — Progress on the Function and Application of Thymosin β4 (opens in a new tab)www.frontiersin.org
Back to overview ↑ - 05
Research publication
Current Reviews in Musculoskeletal Medicine (2025) — Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
- 08
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review / PMC — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.